RCKT Rocket Pharmaceuticals Inc.

-0.17  -1%
Previous Close 17.47
Open 17.47
Price To Book 4.02
Market Cap 780479760
Shares 45,114,437
Volume 113,299
Short Ratio
Av. Daily Volume 240,452

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data released January 3, 2017. Primary endpoint not met.
Primary open-angle glaucoma (POAG)
Phase 2 trial failed - noted July 7, 2017.
Trabodenoson and latanoprost
Phase 1 trial to commence 2Q 2019.
Leukocyte Adhesion Deficiency-I (LAD-I)
Phase 1 dosing of first patient announced March 12, 2019. Initial data due by end of 2019.
Fanconi Anemia (FA)
Phase 1 trial to commence 2Q 2019.
Danon disease

Latest News

  1. Rocket Pharmaceuticals Announces Presentations at the American College of Cardiology 2019 Annual Meeting
  2. Are Insiders Selling Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Stock?
  3. Rocket Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of RP-L102 in the U.S.
  4. Rocket Pharmaceuticals Sponsors Clinical Trial at University of California, Los Angeles (UCLA)
  5. Rocket Pharmaceuticals Reports Full Year 2018 Financial Results and Operational Highlights
  6. Rocket Pharmaceuticals Announces Participation at Upcoming Conferences
  7. Rocket Pharmaceuticals Recognizes Rare Disease Day® 2019
  8. Rocket Pharmaceuticals Announces Publication of Comprehensive Review of Danon Disease Cases in the International Journal of Cardiology
  9. Rocket Pharmaceuticals Announces Participation in Fireside Chat at the 8th Annual SVB Leerink Global Healthcare Conference
  10. Rocket Pharmaceuticals Announces Clearance of IND for RP-A501 Gene Therapy for Danon Disease
  11. Rocket Pharmaceuticals to Join NASDAQ Biotechnology Index
  12. Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
  13. Rocket Pharmaceuticals Prices Public Offering of Common Stock
  14. Rocket Pharmaceuticals (RCKT) in Focus: Stock Moves 7.2% Higher
  15. Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations for RP-L102 Gene Therapy for Fanconi Anemia
  16. Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
  17. Rocket Pharmaceuticals and REGENXBIO Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector
  18. Rocket Pharmaceuticals Announces Preclinical Data for AAV-Based RP-A501, the First Investigational Gene Therapy Program for a Monogenic Heart Failure Syndrome
  19. REGENXBIO and Rocket Pharmaceuticals Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector
  20. Rocket Pharmaceuticals to Host Conference Call to Reveal First AAV Gene Therapy Program